Rapport Therapeutics (RAPP) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rapport Therapeutics (RAPP) has outperformed Sarepta Therapeutics (SRPT) over the past year, losing 15.0% versus a loss of 24.6%. Sarepta Therapeutics is the larger company by market cap ($1.43 billion vs $1.37 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RAPP | SRPT |
|---|---|---|
| Share price | $23.16 | $13.33 |
| Market cap | $1.37B | $1.43B |
| 1-day change | -1.82% | -5.93% |
| YTD return | -23.67% | -38.06% |
| 1-year return | -15.01% | -24.65% |
| 5-year return | — | -83.26% |
| P/E ratio (TTM) | — | 666.50 |
| Forward P/E | — | 8.87 |
| EPS (TTM) | $-3.17 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.20B |
| Revenue growth (YoY) | — | +15.58% |
| Net income (latest FY) | $-111.48M | $-713.41M |
| Gross margin | — | 98.84% |
| Operating margin | — | -31.83% |
| Net margin | — | -32.45% |
| 52-week high | $52.93 | $24.68 |
| 52-week low | $22.06 | $13.25 |
| Distance from 52-week high | -56.24% | -45.99% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +177.25% | +63.32% |
| Average volume | 790.62K | 2.70M |
| Shares outstanding | 59.28M | 107.24M |
| Employees | 84 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
RAPP vs SRPT FAQ
Which is bigger, Rapport Therapeutics or Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.43B compared with $1.37B for Rapport Therapeutics (RAPP).
Which stock has performed better over the past year, RAPP or SRPT?
RAPP returned -15.01% over the past 12 months, compared with -24.65% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Rapport Therapeutics and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.